These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16154854

  • 1. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L, Luppi M, Riva G, Marasca R, Martinelli S, Torelli G.
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [Abstract] [Full Text] [Related]

  • 2. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC.
    Cancer; 2009 Feb 01; 115(3):561-70. PubMed ID: 19117346
    [Abstract] [Full Text] [Related]

  • 3. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.
    Haematologica; 2004 Jan 01; 89(1):49-57. PubMed ID: 14754606
    [Abstract] [Full Text] [Related]

  • 4. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
    Piccaluga PP, Malagola M, Amabile M, Rondoni M, Paolini S, Pane F, Russo D, Visani G, Baccarani M, Martinelli G.
    Haematologica; 2004 Oct 01; 89(10):1269-71. PubMed ID: 15477218
    [Abstract] [Full Text] [Related]

  • 5. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
    Brandwein JM, Gupta V, Wells RA, Schuh AC, Schimmer AD, Lipton JH, Messner HA, Yi QL, Chun K, Kamel-Reid S, Minden MD.
    Leuk Res; 2005 Dec 01; 29(12):1381-6. PubMed ID: 15927253
    [Abstract] [Full Text] [Related]

  • 6. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group.
    J Clin Oncol; 2006 Jan 20; 24(3):460-6. PubMed ID: 16344315
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group.
    Br J Haematol; 2008 Nov 20; 143(4):503-10. PubMed ID: 18986386
    [Abstract] [Full Text] [Related]

  • 10. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D, GMALL Study Group.
    Cancer; 2007 May 15; 109(10):2068-76. PubMed ID: 17429836
    [Abstract] [Full Text] [Related]

  • 11. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 May 15; 12(10):3037-42. PubMed ID: 16707599
    [Abstract] [Full Text] [Related]

  • 12. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS, Kim HJ, Lee S, Eom KS, Min WS, Lee JW, Kim CC.
    Eur J Haematol; 2007 Aug 15; 79(2):170-3. PubMed ID: 17608710
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
    Zembutsu H, Yanada M, Hishida A, Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T, Nakamura Y, Ohno R.
    Int J Oncol; 2007 Aug 15; 31(2):313-22. PubMed ID: 17611687
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 15; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 18. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ.
    Haematologica; 2006 May 15; 91(5):663-6. PubMed ID: 16627251
    [Abstract] [Full Text] [Related]

  • 19. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
    Wassmann B, Gökbuget N, Scheuring UJ, Binckebanck A, Reutzel R, Gschaidmeier H, Hoelzer D, Ottmann OG, GMALL Study Group.
    Ann Hematol; 2003 Nov 15; 82(11):716-20. PubMed ID: 14648032
    [No Abstract] [Full Text] [Related]

  • 20. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.
    J Clin Oncol; 2005 Oct 20; 23(30):7583-93. PubMed ID: 16234522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.